Australia is eagerly awaiting the arrival of retatrutide, a groundbreaking dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, https://bike-giant-stance412321.reflectblog.com/313429/novo-nordisk-s-retatrutide-australia-a-potential-solution-for-weight-management